Invanz is a drug owned by Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc. It is protected by 8 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 15, 2017. Details of Invanz's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5952323 (Pediatric) | Carbapenem antibiotic |
Nov, 2017
(7 years ago) |
Expired
|
| US5952323 | Carbapenem antibiotic |
May, 2017
(7 years ago) |
Expired
|
|
US5478820 (Pediatric) | Antibiotic compounds |
May, 2016
(8 years ago) |
Expired
|
| US5478820 | Antibiotic compounds |
Nov, 2015
(8 years ago) |
Expired
|
|
US7342005 (Pediatric) | Antibiotic compounds |
Aug, 2013
(11 years ago) |
Expired
|
|
US5652233 (Pediatric) | Antibiotic compounds |
Aug, 2013
(11 years ago) |
Expired
|
| US7342005 | Antibiotic compounds |
Feb, 2013
(11 years ago) |
Expired
|
| US5652233 | Antibiotic compounds |
Feb, 2013
(11 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Invanz's patents.
Latest Legal Activities on Invanz's Patents
Given below is the list of recent legal activities going on the following patents of Invanz.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 08 Apr, 2016 | US7342005 |
| Patent Issue Date Used in PTA Calculation Critical | 11 Mar, 2008 | US7342005 |
| Recordation of Patent Grant Mailed Critical | 11 Mar, 2008 | US7342005 |
| Issue Notification Mailed Critical | 20 Feb, 2008 | US7342005 |
| Dispatch to FDC | 11 Feb, 2008 | US7342005 |
| Application Is Considered Ready for Issue Critical | 09 Feb, 2008 | US7342005 |
| Issue Fee Payment Verified Critical | 17 Jan, 2008 | US7342005 |
| Issue Fee Payment Received Critical | 17 Jan, 2008 | US7342005 |
| Mail Notice of Allowance Critical | 17 Oct, 2007 | US7342005 |
| Notice of Allowance Data Verification Completed Critical | 15 Oct, 2007 | US7342005 |
US patents provide insights into the exclusivity only within the United States, but Invanz is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Invanz's family patents as well as insights into ongoing legal events on those patents.
Invanz's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Invanz's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 15, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Invanz Generic API suppliers:
Ertapenem Sodium is the generic name for the brand Invanz. 6 different companies have already filed for the generic of Invanz, with Acs Dobfar Spa having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Invanz's generic
How can I launch a generic of Invanz before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Invanz's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Invanz's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Invanz -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 1 g/vial | 21 Dec, 2012 | 1 | 15 May, 2017 | Extinguished |
About Invanz
Invanz is a drug owned by Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc. It is used for treating bacterial infectious diseases. Invanz uses Ertapenem Sodium as an active ingredient. Invanz was launched by Msd Sub Merck in 2001.
Approval Date:
Invanz was approved by FDA for market use on 21 November, 2001.
Active Ingredient:
Invanz uses Ertapenem Sodium as the active ingredient. Check out other Drugs and Companies using Ertapenem Sodium ingredient
Treatment:
Invanz is used for treating bacterial infectious diseases.
Dosage:
Invanz is available in injectable form for intramuscular, intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 1GM BASE/VIAL | INJECTABLE | Prescription | INTRAMUSCULAR, INTRAVENOUS |